Table 4.
Distant relapse-free interval and overall survival according to histologic type
| Distant recurrence-free interval | |||||
|---|---|---|---|---|---|
| N | Distant recurrence | 14-year DRFI % ± SE | HR (95% CI) | P value* | |
| Full cohort | 0.52 (0.36–0.75) | 0.0005 | |||
| Medullary | 127 | 29 | 76 ± 4 | ||
| Ductal | 8096 | 2695 | 64 ± 1 | ||
| Node-negative | 0.53 (0.17–1.65) | 0.27 | |||
| Medullary | 26 | 3 | 88 ± 6 | ||
| Ductal | 2572 | 486 | 80 ± 1 | ||
| Node-positive | 0.54 (0.37–0.80) | 0.002 | |||
| Medullary | 101 | 26 | 73 ± 5 | ||
| Ductal | 5524 | 2209 | 57 ± 1 | ||
| Chemotherapy | 0.57 (0.37–0.87) | 0.009 | |||
| Medullary | 85 | 22 | 72 ± 5 | ||
| Ductal | 6276 | 2190 | 63 ± 1 | ||
| No chemotherapy | 0.41 (0.19–0.87) | 0.02 | |||
| Medullary | 42 | 7 | 85 ± 6 | ||
| Ductal | 1820 | 505 | 70 ± 1 | ||
| Restricted cohort | 0.24 (0.10–0.58) | 0.002 | |||
| Medullary | 47 | 5 | 89 ± 5 | ||
| Ductal | 1407 | 490 | 63 ± 1 | ||
| Node-negative | 0.40 (0.10–1.62) | 0.20 | |||
| Medullary | 19 | 2 | 89 ± 7 | ||
| Ductal | 463 | 107 | 76 ± 2 | ||
| Node-positive | 0.22 (0.07–0.69) | 0.01 | |||
| Medullary | 28 | 3 | 89 ± 6 | ||
| Ductal | 944 | 383 | 57 ± 2 | ||
| Chemotherapy | 0.28 (0.10–0.76) | 0.01 | |||
| Medullary | 32 | 4 | 88 ± 6 | ||
| Ductal | 1181 | 415 | 63 ± 1 | ||
| No chemotherapy | 0.14 (0.02–0.98) | 0.05 | |||
| Medullary | 15 | 1 | 93 ± 6 | ||
| Ductal | 226 | 75 | 65 ± 3 | ||
|
Overall survival (OS) | |||||
| N | Deaths | 14-year OS % ± SE | HR (95% CI) | P value* | |
| Full cohort | 0.75 (0.58–0.97) | 0.03 | |||
| Medullary | 127 | 59 | 66 ± 4 | ||
| Ductal | 8096 | 3560 | 57 ± 1 | ||
| Node-negative | 0.88 (0.44–1.76) | 0.71 | |||
| Medullary | 26 | 8 | 80 ± 8 | ||
| Ductal | 2572 | 738 | 73 ± 1 | ||
| Node-positive | 0.76 (0.57–1.00) | 0.05 | |||
| Medullary | 101 | 51 | 62 ± 5 | ||
| Ductal | 5524 | 2822 | 49 ± 1 | ||
| Chemotherapy | 0.71 (0.51–1.00) | 0.05 | |||
| Medullary | 85 | 35 | 65 ± 5 | ||
| Ductal | 6276 | 2742 | 57 ± 1 | ||
| No chemotherapy | 0.67 (0.44–1.02) | 0.06 | |||
| Medullary | 42 | 24 | 67 ± 7 | ||
| Ductal | 1820 | 818 | 58 ± 1 | ||
| Restricted cohort | 0.55 (0.34–0.89) | 0.01 | |||
| Medullary | 47 | 17 | 74 ± 7 | ||
| Ductal | 1407 | 656 | 54 ± 1 | ||
| Node-negative | 0.86 (0.38–1.94) | 0.71 | |||
| Medullary | 19 | 6 | 78 ± 10 | ||
| Ductal | 463 | 149 | 70 ± 2 | ||
| Node-positive | 0.53 (0.29–0.98) | 0.04 | |||
| Medullary | 28 | 11 | 71 ± 9 | ||
| Ductal | 944 | 507 | 46 ± 2 | ||
| Chemotherapy | 0.52 (0.29–0.95) | 0.03 | |||
| Medullary | 32 | 11 | 74 ± 8 | ||
| Ductal | 1181 | 554 | 53 ± 2 | ||
| No chemotherapy | 0.52 (0.22–1.21) | 0.13 | |||
| Medullary | 15 | 6 | 73 ± 11 | ||
| Ductal | 226 | 102 | 58 ± 3 | ||
Log-rank P values are stratified by pathologist review.
DRFI, distant recurrence-free interval; CI, confidence interval; HR, hazard ratio; OS, overall survival; SE, standard error.